• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 18th January 2018

A New Way of Presenting Health States in Valuation Studies

Recently published in the European Journal of Health Economics is a paper on valuing health states ‘in context’ using a discrete choice experiment. In health state valuation studies, health states are typically presented as a series of sentences, each describing…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Figure-1_1

Recently published in the European Journal of Health Economics is a paper on valuing health states ‘in context’ using a discrete choice experiment.

In health state valuation studies, health states are typically presented as a series of sentences, each describing a health dimension and severity ‘level’. Differences between the severity levels can be subtle, and semantic confusion about which is ‘worse’ can lead to logically inconsistent valuation data. This conventional way of presenting health states, in the context of a discrete choice experiment, is shown in Figure 1.

Recently published in the European Journal of Health Economics is a paper examining the impact of changing the way health states are presented in valuation studies, using the EQ-5D-5L – a patient-reported outcome (PRO) measure – as an example. The paper is authored by OHE’s Amanda Cole, Koonal Shah, Yan Feng and Nancy Devlin, in collaboration with Brendan Mulhern of the University of Technology Sydney.

Figure 1. Standard presentation of health states in EQ-5D-5L valuation studies

An online two-arm discrete choice experiment was conducted, with respondents in the test (context) arm seeing health states in the ‘context’ of the entire EQ-5D-5L descriptive system – as shown in Figure 2. The intention was to mimic the way in which patients see these health states when self-reporting their own health. This ensures that the health state being valued is as similar as possible to the one that is being described.

Figure 2. Presentation of health states in the test (context) arm

The results show that presenting health states ‘in context’ can significantly reduce the selection of logically dominated health states. Comparing conditional logit modelling results, coefficients are ordered as expected in both arms, but the magnitude of decrements between levels is larger in the test arm. The authors conclude state health state presentation is a key consideration in the design of valuation studies.

This suggests that presenting PRO health states ‘in context’ may provide a way of helping respondents more readily to differentiate between the pairs of health states they are being asked to value in discrete choice experiments. The new approach to presenting health states could arguably offer even more advantage in time trade-off studies, where health states are presented one at a time. We hope to explore this in further research.

Cole, A., Shah, K., Mulhern, B., Feng, Y. and Devlin, N., 2017. Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment. European Journal of Health Economics.  DOI: 10.1007/s10198-017-0905-7

Earlier versions were presented the 2016 EuroQol Plenary Meeting and the 2016 ISPOR European Congress.

Related publications authored by OHE researchers:

  • Devlin, N., Hansen, P., Kind, P. and Williams, A., 2003. Logical inconsistencies in survey respondents’ health state valuations – a methodological challenge for estimating social tariffs. Health Economics, 12(7), pp.529-544. DOI: 10.1002/hec.741
  • Krabbe, P.F.M., Devlin, N.J., Stolk, E.A., Shah, K.K., Oppe, M., van Hout, B., Quik, E.H., Pickard, A.S. and Xie, F., 2014. Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. Medical Care, 52(11), pp.935-943. DOI: 10.1097/MLR.0000000000000178
  • Mulhern, B., Norman, R., Lorgelly, P., Lancsar, E., Ratcliffe, J., Brazier, J. and Viney, R., 2017. Is dimension order important when valuing health states using discrete choice experiments including duration? Pharmacoeconomics, 35(4), pp.439–451. DOI: 10.1007/s40273-016-0475-z
  • Mulhern, B., Shah, K., Janssen, M.F., Longworth, L. and Ibbotson, R., 2016. Valuing health using time trade-off and discrete choice experiment methods: does dimension order impact on health state values? Value in Health, 19, pp.210-217. DOI: 10.1016/j.jval.2015.11.005
  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!